Ensure precision and reliability in your research and manufacturing with our high-fidelity solutions—shop our virus stocks and derivative products online or speak with a representative to place a custom order.
Ensure precision and reliability in your research and manufacturing with our high-fidelity solutions—shop our virus stocks and derivative products online or speak with a representative to place a custom order.
Pharma and biotech leaders trust our expertise in virus production and quality control, backed by our industry leading processes. We ensure the highest standards in virus production and quality control, delivering high-fidelity virus stocks and derivative products for consistent results. Our commitment to regulatory excellence guarantees full compliance with industry standards and industry leading transparency. With accelerated timelines, we provide scalable solutions to meet critical deadlines.
Pharma and biotech leaders trust our expertise in virus production and quality control, backed by our industry leading processes. We ensure the highest standards in virus production and quality control, delivering high-fidelity virus stocks and derivative products for consistent results. Our commitment to regulatory excellence guarantees full compliance with industry standards and industry leading transparency. With accelerated timelines, we provide scalable solutions to meet critical deadlines.
For specialized research needs, we offer on-demand production of virus stocks and derivative products, including wild-type virus strains and reporter-expressing variants. Our team can generate inactivated virus stocks, purified virus preparations, and quantified viral genetic material tailored to your specifications.
Join us at the Palais des congrès de Montréal as we connect with leading virologists and biotech innovators. Our team will be available throughout the conference to discuss our reverse genetics based scalable virus production platform, and custom preclinical and clinical research solutions.
Discover how our high-fidelity virus stocks and custom-engineered viral tools are driving progress in:
Interested in a one-on-one meeting at the event?
Every year, preclinical research in the United States wastes an estimated $28 billion on irreproducible studies...
Whether developing vaccines, testing antivirals, or building diagnostic assays, success depends heavily on the fidelity of the virus stocks used during R&D.
In recent years, reverse genetics has emerged as a more precise and powerful alternative to serial passaging, offering a range of advantages in the production of virus stocks.
Subscribe to our newsletter for industry insights and research updates.
Subscribe to our newsletter for industry
insights and research updates.